Stool test could spot stomach cancer before it spreads
NCT ID NCT07312500
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether testing stool (feces) for certain DNA changes and bacteria genes can help find stomach cancer early. Researchers will follow 3000 people, including those with and without cancer, to see how well the test works. The goal is to improve early diagnosis and track if cancer comes back after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects for this clinical study were obtained from inpatients and outpatient follow-up patients attending the sub-center. Subjects will be identified by the investigator based on subject entry criteria and informed of the contents of the informed consent form. Subjects will have their feces collected at the time of clinic visit or at the time of physical examination and will be tested for fecal methylated DNA and H. pylori gastric cancer susceptibility genes.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥ 18 years old, male or female not limited. 2. Within 90 days, the gastroscopy and/or pathological results confirm the absence of gastric cancer. 3. Patients must be able to fully understand the informed consent form and be able to personally sign it. Exclusion Criteria: 1. Severe heart, liver, kidney dysfunction, or mental illness. 2. History of malignant tumors in the upper gastrointestinal tract. 3. Pregnant women. 4. Those with unclear pathology. 5. Those with unsatisfactory sample retention (such as insufficient sample size).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric (stomach) cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may reveal how well stomach cancer treatment works
- Can a simple blood test predict leukemia risk after cancer therapy?
- When to treat? new trial aims to optimize therapy for oligometastatic esophageal and gastric cancer
- New hope for stomach cancer: experimental drug BHB810 enters human trials
- New drug DA-3501 takes on tough cancers in first human trial
- Algerian gastric cancer study aims to map diagnosis and care